TriMaster: Study of a DPP4 Inhibitor, SGLT2 Inhibitor and Thiazolidinedione as Third Line Therapy in Patients With Type 2 Diabetes.
A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 525 participants.
Also called NCT02653209
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; double masking; primary purpose treatment
- Phase
- Phase 4
- Enrolled
- 525 participants
- Sponsor
- Registry
-
NCT02653209 -
2015-002790-38
-
- Other papers using this trial's data
- Patient preference for second- and third-line therapies in type 2 diabetes: a prespecified secondary endpoint of the TriMaster study
- Patient stratification for determining optimal second-line and third-line therapy for type 2 diabetes: the TriMaster study
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- United Kingdom
- Registry status
- Completed
Technical summary
Registry record NCT02653209. Randomized; double masking; primary purpose treatment. Start 2016-11-01 (actual); primary completion 2021-01 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- TriMaster: Study of a DPP4 Inhibitor, SGLT2 Inhibitor and Thiazolidinedione as Third Line Therapy in Patients With Type 2 Diabetes.
- Acronym
- TriMaster
- Condition
- Type 2 Diabetes
- Intervention (Drug)
- Sitagliptin - DPP4i
- Intervention (Drug)
- Canagliflozin - SGLT2i
- Intervention (Drug)
- Pioglitazone - TZD
- Lead sponsor
- Royal Devon and Exeter NHS Foundation Trust
- Collaborator
- University of Exeter
- Collaborator
- NHS Tayside
- Collaborator
- University of Dundee
- Collaborator
- University of Glasgow
- Collaborator
- Newcastle University
- Collaborator
- King's College London
Record details
- Record id
cardio:ct-nct02653209- Content hash
33a88175afdfde6bce6eb70e4dc3680a37d51cf857c1322ce5ccfadfb0d3de91